Today, Recent Research Analysts’ Ratings Changes for Jazz Pharmaceuticals plc – (JAZZ)

Today, Recent Research Analysts’ Ratings Changes for Jazz Pharmaceuticals plc – (JAZZ)
Several analysts have recently updated their ratings and price targets for Jazz Pharmaceuticals plc – (NASDAQ: JAZZ):

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) opened at 111.65 on Friday. Jazz Pharmaceuticals plc – has a 52 week low of $95.80 and a 52 week high of $160.00. The firm has a market capitalization of $6.69 billion, a price-to-earnings ratio of 19.53 and a beta of 1.35. The company has a 50-day moving average of $114.83 and a 200-day moving average of $133.07.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, November 8th. The specialty pharmaceutical company reported $2.57 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.61 by $0.04. The company earned $374 million during the quarter, compared to the consensus estimate of $389.34 million. Jazz Pharmaceuticals plc – had a net margin of 24.81% and a return on equity of 30.50%. Jazz Pharmaceuticals plc -‘s revenue for the quarter was up 9.8% on a year-over-year basis. During the same period in the previous year, the company earned $2.52 EPS. On average, equities analysts forecast that Jazz Pharmaceuticals plc – will post $9.96 earnings per share for the current fiscal year.

Related posts

Leave a Comment